MedElevator
Войти в исследования The Journal of infection · 2014
Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis.
Оценочное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shin Beomsu, Koh Won-Jung, Jeong Byeong-Ho, Yoo Hongseok, Park Hye Yun, Suh Gee Young, Kwon O Jung, Jeon Kyeongman
Аннотация
BACKGROUND: A serum galactomannan (GM) antigen test has been widely used to diagnose invasive pulmonary aspergillosis. However, there are limited data on the use of the serum GM antigen test for the serologic diagnosis of chronic pulmonary aspergillosis (CPA).
METHODS: Data were collected from all consecutive patients with a clinical suspicion of CPA who underwent a serum GM antigen test.
RESULTS: In total, 334 patients who were suspected to have CPA were eligible for this study and 168 (50%) patients were finally diagnosed with CPA. The serum GM antigen test was positive in 38 (23%) patients with CPA and in 25 (15%) patients without CPA. The sensitivity of the serum GM antigen test was 23% (95% confidence interval [CI], 17-30%), and its specificity was 85% (95% CI, 79-90%), with positive and negative predictive values of 60% (95% CI, 47-72%) and 52% (95% CI, 46-58%), respectively. The accuracy of the test was 54%. The area under the receiver operating characteristic curve was 0.538 (95% CI, 0.496-0.580).
CONCLUSION: The serum GM antigen test could not be used for the serologic diagnosis of CPA.
METHODS: Data were collected from all consecutive patients with a clinical suspicion of CPA who underwent a serum GM antigen test.
RESULTS: In total, 334 patients who were suspected to have CPA were eligible for this study and 168 (50%) patients were finally diagnosed with CPA. The serum GM antigen test was positive in 38 (23%) patients with CPA and in 25 (15%) patients without CPA. The sensitivity of the serum GM antigen test was 23% (95% confidence interval [CI], 17-30%), and its specificity was 85% (95% CI, 79-90%), with positive and negative predictive values of 60% (95% CI, 47-72%) and 52% (95% CI, 46-58%), respectively. The accuracy of the test was 54%. The area under the receiver operating characteristic curve was 0.538 (95% CI, 0.496-0.580).
CONCLUSION: The serum GM antigen test could not be used for the serologic diagnosis of CPA.